Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market

Future Market Insights suggests that within the MRSA testing landscape, the convergence of rapid molecular diagnostics with next-generation sequencing is enabling simultaneous pathogen identification and antimicrobial resistance profiling at the point of care. FMI analysts identify the strategic partnership between cartridge-based PCR platforms and nanopore sequencing firms as the central pivot point, effectively creating a diagnostic workflow that can detect MRSA and characterize its resistance mechanisms in a single sample run.